CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-03 | Gibson Christopher Chief Executive Officer | Gift | −1,338 | 955,048 | ||
| 2023-05-03 | Gibson Christopher Chief Executive Officer | Exercise or conversion | +31,250 | $2.48 | $78K | 986,298 |
| 2023-05-03 | Gibson Christopher Chief Executive Officer | Sale | −33,073 | $4.71 | $156K | 953,225 |
| 2023-05-03 | Gibson Christopher Chief Executive Officer | Conversion | +4,000 | 4,000 | ||
| 2023-05-03 | Gibson Christopher Chief Executive Officer | Sale | −4,000 | $4.91 | $20K | 0 |
| 2023-05-03 | Gibson Christopher Chief Executive Officer | Conversion | +20,000 | 20,000 | ||
| 2023-05-03 | Gibson Christopher Chief Executive Officer | Sale | −20,000 | $4.90 | $98K | 0 |
| 2023-05-03 | Gibson Christopher Chief Executive Officer | Conversion | +1,000 | 1,000 | ||
| 2023-05-03 | Gibson Christopher Chief Executive Officer | Sale | −1,000 | $4.92 | $5K | 0 |
| 2023-05-03 | Gibson Christopher Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −31,250 | 625,000 | ||
| 2023-05-03 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −1,338 | 6,551,496 | ||
| 2023-05-03 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −4,000 | 531,000 | ||
| 2023-05-03 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −20,000 | 488,000 | ||
| 2023-05-03 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −1,000 | 122,875 | ||
| 2023-04-21 | Li Dean Y Director | Gift | −627,705 | 0 | ||
| 2023-04-03 | Dar Zavain Director | Grant or award | +1,996 | 57,569 | ||
| 2023-03-02 | Gibson Christopher Chief Executive Officer | Conversion | +3,000 | 966,710 | ||
| 2023-03-02 | Gibson Christopher Chief Executive Officer | Gift | −3,000 | 963,710 | ||
| 2023-03-02 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −3,000 | 6,552,834 | ||
| 2023-02-02 | Gibson Christopher Chief Executive Officer | Conversion | +3,000 | 966,710 |
Page 40 of 41 · 805 trades